Peleg-Raibstein D, Knuesel I, Feldon J
Laboratory of Behavioural Neurobiology, Swiss Federal Institute of Technology (ETH Zurich), Schorenstrasse 16, CH-8603 Schwerzenbach, Switzerland.
Behav Brain Res. 2008 Aug 22;191(2):190-201. doi: 10.1016/j.bbr.2008.03.037. Epub 2008 Apr 8.
Based on the 'endogenous dopamine sensitization' hypothesis of schizophrenia the present study employed a repeated amphetamine administration regime in order to investigate the behavioral, neurochemical and neuroanatomical consequences following short- and long-term withdrawal periods. The escalating amphetamine administration schedule consisted of three injections per day over a 6-day period with the dosage ranging from 1 to 8 mg/kg. It was demonstrated that following both short- (4 days) and long-term (66 days) withdrawal periods latent inhibition (LI) and prepulse inhibition (PPI), two translational paradigms highly relevant to schizophrenia, were disrupted. A challenge injection verified sensitization in two different cohorts of animals at 40 and 70 days following cessation of treatment. Neurochemical evaluation demonstrated a reduction in dopamine levels in the caudate-putamen and nucleus accumbens core and shell as well as an enhanced utilization ratio in the caudate-putamen after both withdrawal periods. Similar to the findings from post-mortem studies of brains of schizophrenic patients, a downregulation of glutamic acid decarboxylase 67 (GAD67) immunoreactivity was found in the hippocampus, prefrontal cortex, thalamus, and amygdala in amphetamine pretreated animals following longer withdrawal periods. This was not accompanied by enhanced neurotoxicity or reactive gliosis as demonstrated by the immunohistological analysis using the apoptotic marker activated Caspase-3 and GFAP (glial fibrillary acidic protein; a marker for astrocytes) following both short- and long-term withdrawal periods. In conclusion, it is suggested that these findings constitute a highly reliable and valid animal model of schizophrenia.
基于精神分裂症的“内源性多巴胺致敏”假说,本研究采用重复给予苯丙胺的方案,以探究短期和长期戒断期后的行为、神经化学和神经解剖学后果。递增的苯丙胺给药方案包括在6天内每天注射3次,剂量范围为1至8毫克/千克。结果表明,在短期(4天)和长期(66天)戒断期后,潜在抑制(LI)和前脉冲抑制(PPI)这两种与精神分裂症高度相关的转化范式均受到破坏。一次激发注射证实了在停止治疗后40天和70天的两个不同动物队列中出现了致敏现象。神经化学评估显示,在两个戒断期后,尾状核-壳核和伏隔核核心及壳中的多巴胺水平均降低,尾状核-壳核中的利用率提高。与精神分裂症患者大脑的尸检研究结果相似,在长期戒断期后的苯丙胺预处理动物的海马体、前额叶皮质、丘脑和杏仁核中,发现谷氨酸脱羧酶67(GAD67)免疫反应性下调。短期和长期戒断期后,使用凋亡标记物活化的半胱天冬酶-3和GFAP(胶质纤维酸性蛋白;星形胶质细胞的标记物)进行免疫组织学分析表明,这并未伴有神经毒性增强或反应性胶质增生。总之,这些发现表明这是一个高度可靠且有效的精神分裂症动物模型。